Engineered donor cells take aim at returning blood cancers

NCT ID NCT01087294

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 11 times

Summary

This early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and gave them back to the patient. The main goal was to check safety, with 85 participants enrolled, and the treatment required a hospital stay and long-term follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell neoplasm Hodgkins lymphoma Leukemia, B-Cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, B-CELL LYMPHOMA, B-CELL LYMPHOMA, HODGKINS LYMPHOMA, NON-HODGKINS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
National Marrow Donor Program

Minneapolis, Minnesota, 55401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.